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Burkitt lymphoma is endemic in the Equatorial Belt of Africa, its molecular hallmark is an activated, MYC gene mostly due
to a chromosomal translocation. Especially in its endemic clinical variant, Burkitt lymphoma is associated with the oncogenic
Epstein-Barr virus (EBV), and holoendemic malaria acts as an amplifier. Environmental factors may also cooperate in Burkitt
lymphomagenesis in the endemic regions, such as plants used as traditional herbal remedies. Euphorbia tirucalli, a plant known
to possess EBV-activating substances, has a similar geographical distribution to endemic Burkitt’s Lymphoma and is used as
a hedge, herbal remedy and toy in the Lymphoma BeltI. In this study we aimed at determining if exposure to Euphorbia
tirucalli could contribute to lymphomagenesis, and at which extent. Lymphoblastoid and cord blood-derived cell lines were
treated with plant extracts, and the expression of EBV-coded proteins was checked, to assess EBV reactivation. The occurrence
of chromosomal translocations was then investigated by FISH. Our preliminary results suggest that E. tirucalli is able to reactivate
EBV and determine chromosomal alterations, which leads to c-MYC altered expression. The existence of genomic alterationsmight
determine the accumulation of further genetic alteration, which could eventually lead to a transformed phenotype.
1. Introduction
Burkitt’s Lymphoma (BL), a high-grade Non-Hodgkin’s lym-
phoma, is endemic in the Lymphoma Belt of Africa, which
lies between 10◦N and 10◦S of the Equator [1, 2]. Within
these geographical boundaries, BL accounts for up to 70%
of children cancer with rates up to 10 cases of Burkitt’s
Lymphoma per 100,000 children under the age of 14 years
[3]. Burkitt’s Lymphoma characteristically has a transloca-
tion involving a deregulated, activated, MYC gene on chro-
mosome 8 and immunoglobulin genes on chromosome 14,
or, more rarely, chromosomes 2 or 22 [1], though alternative
pathogenetic mechanisms leading to MYC activation have
also been described [4, 5]. Burkitt’s Lymphoma is associated
with the oncogenic Epstein-Barr virus [6], in particular, 98%
of Burkitt’s Lymphoma cases in the Lymphoma belt show
positivity to EBV [7]. EBV is recognised as a Class 1 human
carcinogen and is thought to play a pivotal role in lymphom-
agenesis in endemic Burkitt’s Lymphoma [8]. Holoendemic
malaria acts as an amplifier and has been shown to be able
to activate the latent EBV in B-lymphocytes in children in
the Equatorial Belt [9, 10]. The combination of malaria and
early infection with the Epstein-Barr virus is thought to be
responsible for boosting the incidence of Burkitt’s lymphoma
a hundred-fold in Africa, compared with rates in the France,
and the USA [11, 12]. Children who subsequently develop
the endemic Burkitt’s Lymphoma have raised antibody levels
to the EBV Viral Capsid Antigen (VCA) of EBV several years
before they actually develop the tumour [13]. Raised levels
of this antibody are also found in the relatives of children
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with Burkitt’s Lymphoma [14] and in those who have used
traditional herbal remedies [15], which have been shown to
be capable of activating the EBV [16].
Euphorbia tirucalli, a plant known to possess EBV-acti-
vating substances, has a similar geographical distribution to
endemic Burkitt’s Lymphoma [17] and is used as a hedge,
herbal remedy, and toy in the Lymphoma Belt. This plant
is found significantly more often at the homes of Burkitt’s
Lymphoma patients [17, 18] and the incidence of Burkitt’s
Lymphoma has fallen in Northern Zambia following the
eradication of thickets of E. tirucalli [19].
Euphorbia tirucalli possesses a milky, rubbery sap which
contains a 4-deoxyphorbol ester [20] closely related to the
tumour-promoter substance TPA (12-O-tetra-decanoy-
phorbol-13-acetate), which is derived from another Eu-
phorbia, Croton tiglium. These TPA-related extracts of Eu-
phorbia tirucalli present in the plant are secreted into the soil
around the plant in active form [21] and can activate the
latent EBV within the cell [16, 22], enhance EBV-mediated
cell transformation [21], and modulate EBV-specific T-cell
activity [21], myelopoiesis, and cellular immunity [23].
EBV and TPA can work synergistically in nude mice to
produce both T- and B-cell lymphomas [24]. TPA’s activity
is also potentiated by the association with nucleic acids.
Other plants commonly found in the Lymphoma belt and
elsewhere in the tropics, typically those belonging to the
Euphorbiaceae, and Thymelaeaceae families, are also known
to induce the EBV lytic phase [16]. Some, but not all of
these Euphorbiae, contain identical or similar phorbol esters
to those found in E. tirucalli [25]. EBV-activation has been
shown to be dependent on cellular protein kinase C (PKC),
irrespective of the extracts’ tumour-promotion abilities [26].
The TPA-related substances present in E. tirucalli could be
expected to exhibit similar properties to those of TPA.
A research paper of the early nineties reported that
E. tirucalli extracts can induce chromosomal abnormalities
when added to EBV-infected cord blood B-lymphocytes [27].
Aya et al. showed that the cells multiplied rapidly following
exposure to the extracts and, after one year of culture, ten
percent of the chromosomal abnormalities induced by these
plant extracts aﬀected chromosome 8 with activation of the
oncogene MYC, thus reproducing the crucial translocation
characterizing Burkitt’s Lymphoma [27], and that cells
treated with the Euphorbia extracts produced lymphomas
when injected into nude mice [27].
These observations suggest that Euphorbia tirucalli ex-
tracts and, possibly, extracts of other plants, which are known
to have similar EBV-activating properties, in conjunction
with other environmental factors, could play an important
role in lymphomagenesis in endemic African Burkitt’s
Lymphoma. Despite the interesting observation reported
by Aya in the early nineties, no further study since then
has elucidated the molecular mechanisms by which some
plant extracts may act as a cofactor in lymphomagenesis.
Therefore, it is also interesting trying to explain the close
link between the geographic distribution of E. tirucalli and
the incidence of BL in the endemic areas. The aim of our
study was to determine if exposure to E. tirucalli extracts
could result in EBV reactivation and induction of genomic
alteration, whichmight contribute to transformation. There-
fore, we treated both a lymphoblastoid cell line (LCL) and
a cord-blood- (CB-) derived cell line newly infected with
EBV with this plant extracts. It was considered that the LCLs
are likely to have accumulated preexisting genetic abnor-
malities [28] having been cultured for a number of years,
whereas the cord-blood cell line should be a better in vitro
model to mimic the eﬀects of the plant extracts in vivo on
EBV-infected cells. Cells were treated with diﬀerent concen-
trations of E. tirucalli, and wemonitored its eﬀect on cell pro-
liferation, EBV antigen expression, and induction of genomic
alterations, such as chromosomal translocations.
Our results indicate that exposure to the plant extracts
is able to reactivate EBV from its latent phase, as indicated
by the expression of the EBV Zebra antigen following the
treatment. In addition, the expression of EBV early antigens
was also observed, along with a marked up regulation of
LMP1, EBNA1, and EBNA2. In addition, though the specific
chromosomal translocations present in Burkitt’s lymphoma
were not detected after E. tirucalli exposure, we observed
the occurrence of polysomies involving chromosome 8, as
demonstrated by the existence of multiple signals for MYC
by FISH, which may result in overexpression of c-MYC, both
at the mRNA and the protein level. In addition, increased
expression for BCL2 was also observed, even in the absence
of any genetic translocations involving this gene.
All together, our results suggest that E. tirucalli, through
EBV reactivation and induction of genetic alterations leading
to MYC overexpression, could contribute to the malignant
transformation process.
2. Materials and Methods
2.1. Cell Lines and Cell Culture. The human lymphoblastoid
cell line (LCL) was a kind gift of Prof. A. Lanzavecchia (IRB,
Bellinzona, Switzerland). The human cord-blood- (CB-)
derived cell line was obtained from cells newly infected and
immortalized by EBV, following the protocol described by
Pelloquin et al. [29]. Mononucleated cells were isolated from
cord blood by Ficoll fractionation. After isolation, purified
EBV obtained from B95.8 cell line (kindly provided by dr.
M. Kleines, Austria) was added to the cell culture, in a 1 : 1
ratio. Cells were cultured in the presence of Cyclosporin A at
a final concentration 2 μg/mL. The eﬃciency of infection was
demonstrated by cluster formation in the cell culture after an
overnight incubation with the virus. The establishment of the
cell line was achieved after onemonth. Immunophenotype of
the established CB cell line (CD79+, CD34−, CD138−, IRF4−,
BCL2+, and BCL6−) was assessed as described below. Before
treatment, cell caryotype was also assessed to confirm
the absence of chromosomal translocations and aneuploi-
dies. An EBV-negative Burkitt lymphoma-derived cell line
(Ramos) was also used and treated as follows. For daily
experiments and treatment with E. tirucalli, cells were cul-
tured in RPMI supplemented with 10% FBS, 1% l-glutamine,
penicillin/streptomycin, with 5% CO2, at 37◦C.
2.2. Immunocytochemisty. Immunocytochemical studies
(ICC) were performed on representative cell smears of both
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treated and untreated cells using microwave pretreatment or
proteolytic digestion of slides for antigen retrieval. A large
panel of antibodies (Table 1) recognizing the various EBV
antigens was applied, in conjunction with the streptavidine-
peroxidase method (Ultravision Detection System Anti-
Polyvalent, HRP by Lab Vision Corporation, and LiquidDAB
Substrate Chromogen System by DAKO), to visualize anti-
body binding. Protein expression was then quantified by
counting the percentage of positive cells per HPF in 10 ran-
domly chosen HPFs.
2.3. E. tirucalli Treatment and Cell Proliferation. E. tirucalli
plant extracts were prepared as described by Ito et al. [30].
Briefly, E. tirucalli extracts were obtained using 200mL ether
under reflux for 72 hours. The ethereal solution was then
evaporated down and the resultant oily extracts were then
dissolved in methanol and served as the test substance for
EBV antigen activation. Cells were treated with diﬀerent
concentration of E. tirucalli (0.1, 0.5, 1, and 10 μg/mL),
resolved in methanol. As a normal control, untreated cells
were cultured with the same amount of methanol. For the
proliferation assay, cells were counted each day for 4 days.
Statistical significance was assessed by the analysis of variance
(ANOVA) test. For detection of EBV-specific responses,
Ramos cells, an EBV-negative Burkitt lymphoma-derived cell
line, were used as negative control and were cultured as
previously described.
2.4. Cell Death Analysis. Cell death was evaluated by several
approaches. Cell viability was checked by Trypan Blue exclu-
sion test. Cell cycle analysis was performed by flow cytom-
etry on a FACStar (BD Bioscience, CA). Forward Scatter
(FSC) and Side Scatter (SSC) signals were recorded in linear
mode. Dead cells and debris were gated out using scatter
properties of the cells and additionally using propidium
iodide (PI) at a concentration of 1 μg/mL. Data was analyzed
using CellQuest software (BD Bioscience, CA). Apoptosis
was detected by DNA laddering on a 1% agarose gel.
Caspase staining for caspase 3 and 8 was detected by im-
munocytochemistry, as previously described.
2.5. Fluorescence In Situ Hybridization (FISH). Briefly, MYC
and BCL2 rearrangements were sought using the MYC FISH
DNA Probe-Split Signal using standard procedures (BCL2,
IgH, IgL, BCL6, break-apart probes, and MYC dual color
probe). Briefly, smeared cells were air-dried, immersed in a
jar filled with pretreatment solution, and warmed at 98◦C
for 10min by means of a Whirlpool JT 356 microwave.
Subsequently, the slides were cooled for 15min at RT.
After two passages of 3min each inWash Buﬀer, excess buﬀer
was tapped oﬀ and the slides digested with cold Pepsin for
20min in a Dako Cytomation Hybridizer (Dako, Denmark).
The slides were then washed twice in Wash Buﬀer for 3min,
dehydrated using increasing graded ethanol series, air-dried,
and finally 10 μL of probe mix were applied to each tissue
section. The slides, covered with coverslip and sealed with
rubber cement, were then incubated in the DakoCytomation
Hybridizer (Dako, Denmark) according to the manufac-
turer’s recommendations. The next day, slides were treated
Table 1: List of antibodies and their respective concentrations.
Primary antibody Dilution Company
EBNA-1 1 : 50 Novus Biologicals
EBNA-2 1 : 50 Dako
ZEBRA 1 : 50 Santacruz
LMP1 1 : 50 Dako
EA 1 : 50 Santacruz
Gp350 1 : 100 Santacruz
BCL6 1 : 30 Dako
BCL2 1 : 150 Dako
CD20 1 : 150 NeoMarkers
CD27 1 : 50 NeoMarkers
IgM 1 : 10000 Dako
CD30 1 : 50 NeoMarkers
CD10 1 : 20 NeoMarkers
CD79 1 : 50 NeoMarkers
IgD 1 : 50 NeoMarkers
Irf-4 1 : 50 Dako
CD138 1 : 100 Dako
Caspase 3 1 : 50 Abcam
with stringency buﬀer at 65◦C for 2min then placed twice in
Wash Buﬀer for 3min, dehydrated using increasing graded
ethanol series, air-dried, and counterstained applying 15 μL
of Fluorescence Mounting Medium. Hybridization signals
were visualized using a Leica microscope equipped with
a triple-band filter for detecting green fluorescent protein
(GFP)/spectrum green, Texas red/spectrum orange, and
DAPI/spectrum blue. Images were captured and archived
using Leica FW4000 software. One hundred nonoverlapping
interphase nuclei were scored for each tumor specimen. In
normal nuclei, two yellow fusion signals (2F) are detected,
whereas in nuclei with translocations, a yellow (or red-
green juxtaposed) signal is obtained from one red and one
green segregated signal (1F1R1G). The results were further
confirmed by additional FISH analysis using split-signal
probes for IgH and IgL loci as well as an LSI IGH/MYC
CEP 8 Tri-color dual-fusion probe (Vysis, Abbott Molecular
IL, USA) specific for the detection of the translocation
t[8; 14]. All reagents, instruments, and split-signal probes
were kindly provided by DakoCytomation (Glostrup, Den-
mark). To specifically detect chromosome 8, the centromeric
probe Zyto Light SPEC CMYC/CEN8 Dual Color Probe
(ZytoVision, Germany) has been used. To establish the
MYC:chromosome 8 ratio, 100 nuclei were randomly chosen
and signals for MYC and chromosome 8 were counted.
2.6. qRT-PCR. Real-time PCR for MYC and BCL2 was
performed using FluoCycle SYBR green (Euroclone, Celbio,
Italy) according to the manufacturer’s instructions and
HPRT as an internal control.
Primer sequences for MYC amplified a region of 129 bp:
LEFT: AGCGACTCTGAGGAGGAAC; RIGHT: TGTGAG-
GAGGTTTGCTGTG. Primer sequences for BCL2 amplified
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a region of 258 bp: LEFT: 5′-TTGCCACGGTGGTGGAGG-
A-3′; RIGHT: 5′-ACAGCCAGGAGAAATCAAACAG-3′.
Primer sequences for HPRT amplified a region of 191 bp:
LEFT: AGCCAGACTTTGTTGGATTTG; RIGHT: TTT-
ACTGGCGATGTCAATAAG. Diﬀerences in gene expression
were calculated using the ΔΔCt method [31].
2.7. Indirect Immunofluorescence. For c-MYC detection, cells
were smeared on positively charged slides after E. tirucalli
treatment (Day 5) and fixed in 4% paraformaldehyde in PBS
for 10 minutes at room temperature. Permeabilization was
achieved by washing cells in PBS, 0.2% Triton X-100, and
1% BSA. Saturation was performed for 1 hour at room tem-
perature in goat serum (Zymed laboratories, Milan, Italy).
All of the antibodies were diluted in goat serum. Primary
antibody incubation was carried out at room temperature
for 1 hour, using anti-c-MYC (9E10 sc-40: Santa Cruz
Biotechnology, Santa Cruz, CA) 1 : 50. Secondary goat anti-
mouse antibody, conjugated with Alexafluor568 (Molecular
Probes, Invitrogen, Milan, Italy), was diluted 1 : 100 in goat
serum and incubated at room temperature for 45 minutes.
The slides were examined on an Axiovert 200 microscope
(Carl Zeiss, Germany) and processed with Zeiss software
(Carl Zeiss, Germany). Nuclei were counterstained by DAPI.
3. Results
3.1. E. tirucalli Treatment Aﬀects Cell Proliferation. We treat-
ed LCLs and the cord-blood-derived cell line with increasing
concentrations of E. tirucalli, as reported in Section 2, using
methanol-treated cells as a control. The eﬀects of the treat-
ment on cell proliferation and cell death were monitored. A
dose-dependent reduction in cell proliferation was observed
after E. tirucalli treatment (Figure 1(a)), accompanied by
high rates of cell deaths (Figure 1(b)).
Cell death seemed to be due to necrosis rather than to
apoptosis, as no DNA laddering nor caspase activation was
observed following E. tirucalli treatment (Figures 1(c) and
1(d)). To assess whether cell death was due to the toxicity
eﬀects of the plant extracts or to reactivation of EBV, we treat-
ed an EBV-negative cell line using the same experimental
conditions, and we observed a similar reduction in cell prolif-
eration accompanied by an increase in cell death suggesting
that cell death was due to plant toxicity (Figure 2).
3.2. E. tirucalli Modulates the Expression of EBV-Antigens.
There are three diﬀerent latency programs of EBV, charac-
terized by the diﬀerential expression of its coded genes [32].
In additions, the expression of some EBV-genes, such as
Zebra, indicates the shift from the latent to the lytic phase of
the virus [33]. Reactivation of EBV as a consequence of TPA-
analogous treatment had been reported by literature [24].
We, therefore, treated cells with diﬀerent concentrations of
E. tirucalli andmonitored the expression of EBV-coded genes
by ICC. After E. tirucalli treatment, we observed the expres-
sion of Zebra, which was not expressed by untreated cells.
In addition, enhanced expression of the EBV early antigen
(EA), LMP1 and EBNA2 expression was also observed,
whereas no significant variation of the EBV early antigen
Table 2: Immunocytochemistry (ICC) of EBV-encoded proteins in
cells treated with E. tirucalli at the concentration of 10 μg/mL versus
untreated cells, expressed as percentage of positive cells out of total
cells. Comparable results were obtained in LCL and cord blood-
derived cells.
Control (%) E. tirucalli 10 μg/mL (%)
Zebra 0 6
Ea-d 40 50
LMP1 50 90
Gp350 0 0
EBNA1 5 30
EBNA2 10 80
Table 3: FISH analysis on E. tirucalli treated versus untreated cells.
Control E. tirucalli 10 μg/mL
BCL2 No translocation No translocation
BCL6 No translocation No translocation
IgH (chromosome 14) No translocation No translocation
IgL (chromosome 22) No translocation No translocation
c-MYC (chromosome 8) No translocation
Polysomies, no
translocation
gp350 was detected following E. tirucalli treatment. Higher
concentrations of plant extracts (10 μg/mL) resulted in a
more marked EBV protein expression. Comparable results
were obtained in LCL and cord-blood cell lines. Table 2 sum-
marizes immunocytochemical results obtained in treated
versus untreated cells. Figure 3 shows ICC results.
3.3. E. tirucalli Induces Chromosome 8 Polysomy. E. tirucalli
has been shown to induce genetic alterations, particularly
those involving the oncogene MYC [27]. To detect the onset
of specific chromosomal translocations after E. tirucalli treat-
ment, we performed FISH analysis to identify the most fre-
quently described chromosomal translocations occurring in
aggressive B-cell lymphomas, using probes designed to detect
MYC, BCL-2, BCL6, and their respective Ig partners. Using
this approach, no balanced translocations involving BCL2,
BCL6, IgH, and IgL were detected. Figure 4 summarizes FISH
results for BCL2 and MYC.
Multiple signals for MYC were detected in about 17% of
cells, ranging between 3 and more copies, in contrast to the
normal 2 copies, though no specific chromosomal translo-
cation could be identified. To assess whether these signals
were dependent on gene amplification or to a chromosome 8
polysomy, we used a centromeric probe to detect both MYC
and centromere signals. Our results indicated a chromosome
8 polysomy, as more than 2 signals for the centromeres were
detected, together with multiple signals for MYC (Figure 5).
Table 3 summarizes FISH results.
3.4. c-MYC Expression Is Upregulated following E. tirucalli
Treatment. The presence of multiple copies of MYC is com-
patible with an overexpression of the c-MYC protein, as
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Figure 1: (a) Cord-blood-derived cells were treated with diﬀerent concentration of E. tirucalli for five days, and proliferation has been
monitored. Methanol-treated cells, with no E. tirucalli extract, have been used as a control. A dose-dependent decrease of proliferation rate
is observed in E. tirucalli-treated cells (P < 0.05). The graph is representative of three diﬀerent experiments. Error bars represent standard
deviation between duplicates. (b) Cell cycle analysis by FACS on untreated (upper part) and E. tirucalli-treated cells (lower part). Tables
indicate the percentage of cells in each cell cycle stages, where M1 indicates total number of dead cells (apoptotic and necrotic cells), M2
indicates G0/G1, M3 cells in S phase, and M4 the G2/M phase. Treated cells show a higher number of the M1 fraction. (c) Electrophoresis on
agarose gel of untreated (lanes 1-2) and E. tirucalli-treated cells (lanes 3-4). No DNA laddering indicative of cell death by apoptosis is visible.
(d) ICC for caspase 3. No caspase activation is detected following E. tirucalli treatment.
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Figure 2: To rule out the possibility that the decrease of cell prolif-
eration and the concomitant increase in cell death observed in E.
tirucalli-treated cells was due to induction of the lytic pathway of
EBV, an EBV-negative cell line (Ramos) was cultured in the same
experimental conditions as cord blood derived cells. E. tirucalli
treatment had the same eﬀects on cell proliferation and cell death,
independently of EBV status. Treated cells showed a decreased
cell proliferation (P < 0.05). The graph is representative of three
diﬀerent experiments. Error bars represent standard deviation be-
tween duplicates.
occurs in Burkitt lymphoma. Therefore, we checked the ex-
pression level of c-MYC by qRT-PRC and immunofluores-
cence. As a consequence of chromosome 8 polysomy, up-
regulation of c-MYCwas observed, as expected, at both levels
(Figures 6(a) and 6(b)).
3.5. BCL2 Is Overexpressed following E. tirucalli Treatment.
BCL2 deregulation is often observed in lymphomas, as in the
case of follicular lymphoma. Though FISH revealed the
absence of any chromosomal translocations involving BCL2,
which maps on chromosome 18, we detected up-regulation
of its expression level in treated cells, both at the mRNA
(Figure 6(a)) and protein levels (Figure 7), which may be
compatible with the acquirement of an anti-apoptotic capa-
bility by treated cells.
4. Discussion
A potential transforming capability by E. tirucalli extracts has
been suggested by a single publication in the last twenty years
[27]. No further studies have been performed since then to
highlight through which molecular mechanisms it occurred.
In this study, we report the results on cell proliferation and
cell death, expression of EBV-antigens, and induction of
chromosomal abnormalities in LCL and cord-blood-derived
cell lines after treatment with E. tirucalli plant extracts.
Results have been almost completely matching between the
two cell lines, though the freshly established cord-blood-
derived cell line is more likely to represent the in vivo situ-
ation in respect with an LCL, as a prolonged in vitro culture
in the latter could determine the accumulation of preexisting
genetic abnormalities.
E. tirucalli treatment determined a reduction of cell pro-
liferation and a concomitant increase of cell death. This result
is in contrast to what reported by literature for PBMCs treat-
ed with E. tirucalli [34], which seems to result in an increased
proliferation rate following treatment. Quite interestingly,
we were not able to reproduce these results neither in LCLs
or cord-blood-derived cells. One possible explanation could
be that the increase of cell proliferation previously reported
[34] has been observed mostly on the CD3+ subpopulation
within PBMC, which represents lymphoid T-cells, whereas
our results are referred to EBV-infected B-cells.
Cell death was quite high in all the treated cells, being
highest with the highest concentrations and seemed to
depend on necrosis due to the plant toxicity, rather than to
apoptosis, as no DNA laddering nor caspase activation was
detected in cells treated with E. tirucalli (Figures 1(c) and
1(d)). The possibility that cell death was due to activation
of the lytic cycle of EBV, as possibly suggested by Zebra
expression, was ruled out by treating an EBV-negative cell
line using the same experimental conditions. Cell death levels
in this cell line were comparable to those observed in EBV-
positive cells, thus suggesting that cell death was due to plant
toxicity.
On the contrary, treatment with E. tirucalli extracts
modulated the expression of EBV-antigens. In particular, the
expression of early antigens and a marked upregulation of
LMP1 were observed after treatment. LMP1 expression may
be relevant for NF-κB activation [35] and apoptosis [36]. A
similar pattern of expression of EBV antigens expression was
observed in LCL and cord blood cells, with the exception of
gp350, which was not expressed in cord-blood after treat-
ment, whereas a weak expression was observed in LCL.
Although it has been previously reported that cells
treated with E. tirucalli and cultured for one year accumu-
lated genetic abnormalities, here we report for the first time
that as less as a five-day treatment of E. tirucalli was able to
determine genomic abnormalities both in LCL and CB. In
particular, in both cases, polysomies were observed, being
more evident the higher the concentration of E. tirucalli
was. The possibility that the observed polysomies observed
in LCL could be due to the accumulation of several genetic
alterations, which may happen to cells cultured for many
years, was ruled out by the observation that polysomies were
induced by E. tirucalli treatment also in newly established
CB cells, with a normal caryotype. In particular, polysomy
of chromosome 8 was detected by FISH through specific
centromeric probes, resulting in an increased number of
copies of the MYC oncogene, as detected by FISH. Though
Aya et al. reported the occurrence of specific chromosomal
translocation in about 10% of treated cells after one year of
culture, we did not detect any specific translocations. One
possible explanation could be that our analyses have been
performed after only five days of treatment, which were
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Figure 3: Immunocytochemistry of untreated (a) and E. tirucalli-treated cells (b). The expression of EBV-coded products was monitored.
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(a) (b)
(c) (d)
Figure 4: FISH analysis for BCL2 (a, b) and MYC (c, d) for untreated (a, c) and E. tirucalli-treated cells (b, d). No balanced translocations
have been detected, though multiple signals for MYC have been identified. Arrows indicate cells with multiple MYC signals.
c-MYC CB + Et
Figure 5: To assess whether multiple MYC signals relied on MYC
gene amplification or on chromosomal 8 polyploidy, a centromeric
probe for chromosome 8 was used. Our results indicated the
presence of multiple signals for chromosome 8 in cells treated with
E. tirucalli, consistent with a polysomy of chromosome 8. Arrows
indicate cells with multiple chromosome 8 and MYC signals.
enough to induce polysomies, but may be not suﬃcient to let
the chromosomal translocation occur. It is presumable that
keeping these already genetically altered cells growing for a
longer period of time might determine the onset and the
accumulation of further genetic alterations, as transloca-
tions. In any case, the increased number ofMYC copies could
mimic the eﬀects of theMYC activation due to the transloca-
tion, as observed in most BL. It is worth noting, nevertheless,
that BL cases lacking MYC translocation do exist, in which
the MYC expression level is increased due to diﬀerent mech-
anisms [4, 5, 37]. Of interest, polysomies were detected only
for chromosome 8, suggesting a predilection for a specific
genetic locus alteration after E. tirucalli treatment.
Interestingly, EBV reactivation may be crucial as its pro-
teins may induce the expression of cellular genes. In particu-
lar, EBNA2may induceMYC expression [38], whereas LMP1
may induce BCL2 expression [39]. This may be of help to
explain BCL2 hyperexpression following E. tirucalli treat-
ment, as no chromosomal translocations, neither genetic
alterations involving BCL2 have been detected. It is reason-
able to hypothesize BCL2 upregulation may be due to LMP1,
whose expression is induced by E. tirucalli. In addition,
EBNA2 overexpression, which is itself induced by E. tirucalli,
may also contribute to hyperexpression of MYC. The obser-
vation of multiple signals for chromosome 8 indicates an
additional mechanism explaining MYC upregulation, which
can synergistically act with EBNA2-induced MYC expres-
sion, in determining higher expression levels of c-MYC. The
overexpression of c-MYC should lead to both an increase of
cell proliferation and cell death, asMYC has proliferative and
proapoptotic eﬀects, thus keeping balanced cell number. E.
tirucalli-treated cells showed a marked upregulation of the
antiapoptotic gene BCL2, though no genetic alterations for
this gene had been detected by FISH. The upregulation of
BCL2 may counteract the proapoptotic eﬀect due to c-MYC
overexpression and could give the treated cells a growth
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Figure 6: (a) qRT-PCR for BCL2 and MYC in untreated and E. tirucalli-treated cells. A marked up-regulation of both genes is observed
following treatment. The graph is representative of three diﬀerent qRT-PCR experiments. Error bars represent standard deviation between
duplicates. (b) Immunofluorescence of untreated (upper panel) or E. tirucalli-treated cells (lower panel). c-MYC expression increases
following treatment. Magnification 40x.
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Figure 7: ICC for BCL2 in untreated (a) and E. tirucalli-treated cells (b). Magnification 40x.
advantage, which may contribute to malignant transforma-
tion.
Collectively, our preliminary data suggest that E. tirucalli
may cooperate in inducing malignant transformation, due to
its modulation of the expression of the latency genes of EBV,
and the upregulation of two key factors as BCL-2 and MYC.
In particular, the overexpression of c-MYC seems to rely
on the induction of polysomies after treatment, rather than
chromosomal translocations.
These observations suggest that Euphorbia tirucalli ex-
tracts and, possibly, extracts of other plants, which are known
to have similar EBV-activating properties, could act as cofac-
tors for lymphomagenesis in endemic African Burkitt’s lym-
phoma.
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